The overall uptake of RSV vaccine is low during its first season in those aged 60 years or older in the United States. The knowledge of the vaccine and its eligibility is limited.

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Flu virus that can lead to paralysis and brain swelling detected in California’s wastewater - This comes on the heels of one ...

After the monoclonal antibody nirsevimab (Beyfortus) became available to prevent respiratory syncytial virus (RSV) in infants ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

The move follows Kennedy’s repeated statements about pharma-backed CDC advisory panels. The Health and Human Services ...

The U.S. Department of Health and Human Services and the National Institutes of Health announced a new initiative called ...